Regenxbio (RGNX) Receivables - Other (2014 - 2025)

Regenxbio's Receivables - Other history runs 10 years deep, the most recent figure standing at $2.0 million for Q4 2025.

• On a quarterly basis, Receivables - Other fell 82.33% year-over-year to $2.0 million in Q4 2025; TTM through Dec 2025 was $2.0 million, a 82.33% decrease from a year earlier, with the FY2025 full-year figure at $10.9 million, down 45.79% from the prior year.
• Receivables - Other declined to $2.0 million in Q4 2025 per RGNX's latest filing, from $22.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $33.5 million in Q2 2022 and bottomed at $28000.0 in Q2 2025.
• The 5-year median for Receivables - Other is $3.5 million (2023), against an average of $10.4 million.
• Biggest YoY gain for Receivables - Other was 8688.03% in 2025; the steepest drop was 99.71% in 2025.
• Year by year, Receivables - Other stood at $1.1 million in 2021, then surged by 486.03% to $6.3 million in 2022, then fell by 20.56% to $5.0 million in 2023, then surged by 126.08% to $11.3 million in 2024, then sank by 82.33% to $2.0 million in 2025.
• Per Business Quant, the three latest RGNX Receivables - Other figures stand at $2.0 million (Q4 2025), $22.8 million (Q3 2025), and $28000.0 (Q2 2025).